Bringing science and development together through news and analysis

  • AIDS vaccines: on the trail of two trials

Shares
The race to be first to develop a vaccine for AIDS could have dire consequences, argues John P. Moore, who says that the competitive mentality of US federal agencies is leading to the wasteful duplication of effort.

Despite claims to the contrary, the present generation of AIDS vaccine candidates will in all probability be of little benefit to populations in the developing world.

The price of failure in a string of trials will be costly — the erosion of public confidence in science’s ability to deliver an effective HIV-1 vaccine.

Link to full text

Reference: Nature 415, 365 (2002)
Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.